Abbreviated New Drug Application (ANDA) Amendment related to the drug vial for preservative-free ket

WILMINGTON, Del., Sept. 15, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx

BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains

KETAFREE could turn NRXP's ketamine opportunity into a commercial business, provided FDA approval le

Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retro

Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retro

HOPE is the first Interventional Psychiatry network to deploy Zeta Surgical's newly FDA-cleared

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP)

NRX Pharmaceuticals (NASDAQ:NRXP) released second-quarter financial results and hosted an earnings c

NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.44) per share which missed the an

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a cl

BTIG analyst Thomas Shrader maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and lowers the

No major deficiencies related to the drug product, ingredients, proposed labeling, Chemistry, Manufa

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 91.1% to $6.04 during Friday's

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx" or the "Company") today issued the fo

First Zeta-navigated TMS treatments have begun at HOPE Therapeutics clinics in West Palm Beach and S

D-Cycloserine (DCS) has been reported to augment the effect of Transcranial Magnetic Stimulation (TM

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals" or the "Company"), a

Tetra Technologies Inc. (NYSE: TTI) shares fell 15.06% in pre-market trading after announcing a $100

NRXP stock fell after hours after NRx Pharmaceuticals announced a public stock offering to raise cap

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals" or the "Company"), a

EMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure

Deployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to

Key highlights from the first quarter of operations under the expanded management team include the f

NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.04) per share. This is a 88.24 pe

NRx Pharma (NRXP) set to release Q1 earnings on May 18. Analysts expect $19.43 million in revenue, w

Preliminary research suggests that D-cycloserine significantly enhances the effect of Transcranial M

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a biopharmaceutical company that focuses on neuroplastic th

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP)

Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and

In the Order, the President notes that, "It is the policy of my Administration to accelerate inn

NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on l

BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains

NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly earnings of $0.20 per share. This is a 125.97 p

The FDA signals its willingness to review NRx Pharmaceuticals' NRX-100 NDA, boosting optimism ar

NRXP has received confirmatory minutes from an in-person Type C guidance meeting at the headquarters

Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation

HC Wainwright & Co. analyst Patrick R. Trucchio maintains NRX Pharmaceuticals (NASDAQ:NRXP) w

BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and

BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and

Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and

Remaining $5.4 million debt was repaid through strategic equity conversion in common stock with no a